Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;38(10):e70002.
doi: 10.1111/ctr.70002.

Recurrence of Primary Sclerosing Cholangitis and De Novo Cholangiocarcinoma After Liver Transplantation: Results From the Brazilian Cholestasis Consortium

Paulo Lisboa Bittencourt  1   2 , Mateus Jorge Nardelli  3 , Luísa Leite Barros  4 , Guilherme Grossi Lopes Cançado  3   5 , Eduardo Luiz Rachid Cançado  4 , Débora Raquel Benedita Terrabuio  4 , Cristiane Alves Villela-Nogueira  6 , Maria Lucia Gomes Ferraz  7 , Liana Codes  1 , Vivian Rotman  6 , Rodrigo Rocco  8 , Guilherme Eduardo Felga  8 , Diogo Delgado Dotta  4 , Adrielly de Souza Martins  9 , Liliana Sampaio Costa Mendes  10 , Marlone Cunha da Silva  11 , Elodie Bonfim Hyppolito  12 , Geisa Perez Medina Gomide  13 , Izabelle Venturini Signorelli  14 , Maria Beatriz de Oliveira  15 , Claudia Alexandra Pontes Ivantes  16 , Maria Chiara Chindamo  6   17 , Valéria Ferreira de Almeida E Borges  18 , Luciana Costa Faria  3 , Claudia Alves Couto  3
Affiliations

Recurrence of Primary Sclerosing Cholangitis and De Novo Cholangiocarcinoma After Liver Transplantation: Results From the Brazilian Cholestasis Consortium

Paulo Lisboa Bittencourt et al. Clin Transplant. 2024 Oct.

Abstract

Background and aim: Primary sclerosing cholangitis (PSC) has been shown to recur after liver transplantation (LT). Some studies have identified certain clinical and laboratory variables associated with an increased risk for recurrent PSC (rPSC) in Caucasians. Furthermore, de novo cholangiocarcinoma (CCA) has been reported anecdotally in patients with rPSC. This study aims to assess the prevalence of rPSC, identify its associated risk factors, and investigate the occurrence of de novo CCA in a highly admixed population from Brazil.

Methods: All patients submitted to LT for PSC enrolled in the Brazilian Cholestasis Study Group database were retrospectively reviewed for the occurrence of rPSC and de novo CCA.

Results: Ninety-six (58 males, mean age 32 ± 13 years) patients with PSC underwent LT. After 90 (39-154) months of follow-up (FU), rPSC was observed in 29 (30%) subjects. There were no significant associations between rPSC and age, gender, concurrent or de novo inflammatory bowel disease, MELD score at the time of LT or allograft rejection. The only factor associated with an increased risk of disease recurrence was time after LT. Although survival was decreased in patients who developed rPSC, this difference was not significant. Only one female patient developed de novo CCA after rPSC, 11 years after LT.

Conclusions: Recurrent PSC was observed in one-third of PSC LT patients in Brazil and was associated with longer time after LT. Despite its frequency, rPSC was not associated with a higher risk of graft loss or a significant reduction in posttransplant survival.

Keywords: cholangiocarcinoma; liver transplantation; primary sclerosing cholangitis; recurrent primary sclerosing cholangitis.

PubMed Disclaimer

References

    1. C. L. Bowlus, L. Arrivé, A. Bergquist, et al., “AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma,” Hepatology 77, no. 2 (2023): 659–702, https://doi.org/10.1002/hep.32771.
    1. T. H. Karlsen, T. Folseraas, D. Thorburn, and M. Vesterhus, “Primary Sclerosing Cholangitis—A Comprehensive Review,” Journal of Hepatology 67 (2017): 1298.
    1. D. Aune, A. Sen, T. Norat, E. Riboli, and T. Folseraas, “Primary Sclerosing Cholangitis and the Risk of Cancer, Cardiovascular Disease, and All‐Cause Mortality: A Systematic Review and Meta‐Analysis of Cohort Studies,” Scientific Reports 11, no. 1 (2021): 10646, https://doi.org/10.1038/s41598‐021‐90175‐w.
    1. T. I. Mehta, S. Weissman, B. M. Fung, J. Sotiriadis, K. D. Lindor, and J. H. Tabibian, “Global Incidence, Prevalence and Features of Primary Sclerosing Cholangitis: A Systematic Review and Meta‐Analysis,” Liver International 41, no. 10 (2021): 2418–2426, https://doi.org/10.1111/liv.15007.
    1. M. J. Nardelli, P. L. Bittencourt, G. G. L. Cançado, et al., “Clinical Features and Outcomes of Primary Sclerosing Cholangitis in the Highly Admixed Brazilian Population,” Canadian Journal of Gastroenterology & Hepatology 2021 (2021): 7746401, https://doi.org/10.1155/2021/7746401.

MeSH terms

LinkOut - more resources